Certara (NASDAQ:CERT) Stock Price Down 4.6% – Should You Sell?

Shares of Certara, Inc. (NASDAQ:CERT) dropped 4.6% during mid-day trading on Thursday . The stock traded as low as $10.39 and last traded at $10.42. Approximately 216,356 shares traded hands during mid-day trading, a decline of 74% from the average daily volume of 838,846 shares. The stock had previously closed at $10.92.

Analysts Set New Price Targets

Several analysts recently issued reports on CERT shares. UBS Group upgraded Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price on the stock in a report on Friday, September 27th. Barclays cut their price target on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research note on Thursday, November 7th. Finally, Robert W. Baird dropped their target price on shares of Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a report on Tuesday, November 5th. Six investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $15.92.

Certara Stock Performance

The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $1.72 billion, a price-to-earnings ratio of -53.55, a PEG ratio of 5.86 and a beta of 1.53. The company’s 50-day simple moving average is $10.81 and its 200-day simple moving average is $12.46.

Certara (NASDAQ:CERT) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. The company had revenue of $94.80 million for the quarter, compared to analyst estimates of $95.51 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The firm’s quarterly revenue was up 10.7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.06 earnings per share. On average, analysts expect that Certara, Inc. will post 0.28 EPS for the current year.

Insiders Place Their Bets

In related news, insider Patrick F. Smith sold 5,409 shares of the company’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the sale, the insider now owns 50,091 shares in the company, valued at $552,503.73. This represents a 9.75 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 2.39% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in CERT. Blue Trust Inc. bought a new stake in Certara during the 2nd quarter valued at $26,000. Innealta Capital LLC bought a new stake in shares of Certara during the second quarter worth about $36,000. KBC Group NV raised its holdings in shares of Certara by 48.2% in the 3rd quarter. KBC Group NV now owns 4,873 shares of the company’s stock worth $57,000 after acquiring an additional 1,584 shares during the last quarter. Intech Investment Management LLC acquired a new stake in shares of Certara in the 2nd quarter worth about $152,000. Finally, Algert Global LLC bought a new position in Certara in the 2nd quarter valued at about $156,000. Institutional investors own 73.96% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.